Handa Pharmaceuticals wins final FDA approval for OMCAZIO as $2.1bn Cabometyx market faces new rival

Handa Pharmaceuticals, Inc. (TPEX: 6620) has received final U.S. Food and Drug Administration approval for OMCAZIO, a differentiated cabozantinib capsule that can be administered without regard to food, converting an earlier tentative approval into authorization for U.S. commercialization. Developed through subsidiary Handa Oncology, OMCAZIO uses a laurylsulfate salt formulation and follows the FDA’s 505(b)(2) pathway rather than functioning as a conventional generic version of Exelixis, Inc.’s CABOMETYX. The treatment is approved across multiple cabozantinib oncology indications, including advanced renal cell carcinoma, first-line renal cell carcinoma in combination with nivolumab, previously treated hepatocellular carcinoma and certain previously treated neuroendocrine tumors. Commercial stakes are meaningful because Exelixis generated $2.113 billion of U.S. CABOMETYX net product revenue in 2025 and another $1.123 billion during the first half of 2026.

The practical differentiation is straightforward. Existing CABOMETYX labeling requires patients to avoid eating for at least two hours before and one hour after dosing, whereas Handa says OMCAZIO can be taken with or without food. For cancer patients receiving a chronic oral medicine alongside multiple other treatments, removing a three-hour food-related scheduling window can create a genuine convenience advantage. Handa still has to demonstrate that convenience is enough to win prescriptions and payer access against an entrenched oncology franchise with extensive clinical evidence and physician familiarity.

Why is OMCAZIO not simply another generic version of CABOMETYX?

Handa pursued OMCAZIO through the 505(b)(2) New Drug Application pathway, which allows a sponsor to rely partly on existing evidence supporting an approved reference medicine while providing additional data required for its differentiated formulation. OMCAZIO uses a different salt form of cabozantinib and was developed through pharmacokinetic and bioavailability work intended to establish appropriate exposure at its own dosage strengths. The product is therefore not described as milligram-for-milligram interchangeable with other cabozantinib formulations.

That distinction matters commercially because the product is competing on formulation rather than merely offering a lower-cost duplicate. Handa can emphasize food flexibility and potentially different absorption characteristics, while Exelixis can defend CABOMETYX through its broad clinical record, physician relationships and existing reimbursement position. The resulting market may behave differently from a traditional generic patent cliff where pharmacies automatically substitute identical products.

The approval also demonstrates why 505(b)(2) development can be attractive to smaller pharmaceutical companies. Instead of funding a full de novo oncology program across every disease indication, Handa can leverage established cabozantinib efficacy while investing in the studies required to support its formulation and labeling. That can compress development cost and time, although commercial success still depends on intellectual-property positioning and actual market access.

How large is the U.S. cabozantinib franchise OMCAZIO is entering?

Exelixis reported $2.123 billion of total U.S. cabozantinib franchise product revenue during 2025, of which $2.113 billion came from CABOMETYX. Revenue continued growing in 2026, with CABOMETYX contributing $570.6 million during the second quarter and $1.123 billion over the first six months, increases of approximately 10% and 9% respectively from the comparable periods. Demand has been supported particularly by combination use with nivolumab in first-line advanced kidney cancer and by expansion in neuroendocrine tumors.

Those figures illustrate the opportunity but should not be mistaken for revenue available automatically to Handa. Oncology prescribing is influenced by contracts, formulary positioning, physician familiarity, clinical evidence and intellectual property, while Exelixis continues actively managing the cabozantinib franchise. Even a modest percentage of a $2 billion-plus U.S. market could be meaningful for Handa Pharmaceuticals, but obtaining that share requires commercial execution that goes far beyond FDA authorization.

The competitive timeline is also strategically important for Exelixis because CABOMETYX currently finances substantial research and development around next-generation medicine zanzalintinib. The company has guided toward $2.325 billion to $2.425 billion of 2026 net product revenue, underscoring the importance of preserving cabozantinib economics as competing formulations and eventual broader generic pressure approach.

Does food flexibility provide enough benefit to change prescribing behavior?

A three-hour fasting window may appear modest compared with efficacy and safety considerations, but oral cancer patients frequently manage complex treatment schedules involving other medicines, meals and side-effect management. Removing food restrictions can simplify adherence and reduce the risk that patients inadvertently take a drug under conditions inconsistent with its label. Handa is therefore targeting an inconvenience that becomes more meaningful when treatment continues for months or years.

The challenge is that physicians rarely switch effective oncology treatments purely for convenience unless the alternative provides comparable access and dependable supply. CABOMETYX has extensive clinical-trial data, established pathways across several tumors and a large commercial support infrastructure. OMCAZIO needs competitive reimbursement and strong distribution before its dosing advantage can materially affect share.

Pricing will be another central variable, but Handa had not disclosed U.S. commercial pricing or a detailed launch timetable when announcing final approval. Without that information, it is premature to assume OMCAZIO will compete principally through discounting. The product’s early commercial positioning will reveal whether Handa Pharmaceuticals aims to maximize convenience-based differentiation, price competition or some combination of both.

What intellectual-property tension still surrounds OMCAZIO?

Handa’s application included patent certifications relating to CABOMETYX, and Exelixis has publicly monitored the 505(b)(2) program while defending its cabozantinib intellectual property. Exelixis has also used regulatory and legal strategies around competing cabozantinib applications more broadly, making patent timing an important component of the eventual commercial landscape. Final FDA approval establishes regulatory authorization, but regulatory approval and freedom to commercialize without intellectual-property constraints are separate questions.

That distinction is important for readers because “final approval” should not automatically be interpreted as proof that every potential patent dispute has disappeared. Handa Pharmaceuticals said the decision authorizes U.S. commercialization and indicated that additional information on commercial availability would follow. Investors should therefore watch actual launch timing, distribution and any further legal disclosures rather than treating the approval date itself as confirmation of immediate full-scale sales.

Exelixis has considerable economic incentive to defend CABOMETYX because the franchise generated more than $2 billion of domestic revenue last year and continues growing. Handa, meanwhile, has invested specifically in a differentiated formulation intended to enter that market. The commercial contest will ultimately depend on how regulatory authorization, patents, pricing and physician demand intersect.

What does Handa’s stock performance say about expectations before final approval?

Handa Pharmaceuticals shares closed at TWD124 on September 11, down 1.98% for the session, after an extraordinary run from TWD75 on August 21. The stock had gained about 65% over those three weeks and reached TWD132 on September 9, indicating that investors had already been building substantial expectations around regulatory and commercial catalysts before the final U.S. decision became public.

That preceding rally makes the eventual post-approval reaction harder to interpret as a simple binary event. Investors now need details Handa Pharmaceuticals has not yet supplied, particularly launch timing, pricing, distribution economics and the extent of any continuing intellectual-property constraints. Approval has established that OMCAZIO is a real commercial asset rather than a tentatively approved program. The next question is whether a food-flexible formulation can convert that regulatory differentiation into meaningful share inside one of oncology’s most successful oral targeted-therapy franchises.